Current Controversies and Challenges in Non–Oncogene-Addicted Synchronous Oligometastatic Non–Small Cell Lung Cancer

It remains under debate whether synchronous oligometastatic NSCLC represents a distinct biological entity or merely a probabilistic imaging finding. Biomarkers such as circulating tumor DNA, microRNA, and radiomics may improve patient selection but require further validation. Clinical trials should prioritize translational research to address these challenges.

Corresponding Author: Lizza E. L. Hendriks, MD, PhD, Department of Pulmonary Diseases, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, PO Box 5800, 6202 AZ, Maastricht, the Netherlands (lizza.hendriks@mumc.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.